{"id":"shr-a1904","safety":{"commonSideEffects":[{"rate":null,"effect":"Immune-related adverse events (irAEs)"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Infusion reactions"}]},"_chembl":{"chemblId":"CHEMBL6068589","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By blocking PD-1, the drug relieves inhibitory signals on T cells, while concurrent TGF-β neutralization reduces immunosuppression in the tumor microenvironment. This dual mechanism aims to overcome resistance to single-agent checkpoint inhibition and enhance T-cell activation and infiltration into tumors.","oneSentence":"SHR-A1904 is a bispecific antibody that simultaneously engages PD-1 on immune cells and TGF-β in the tumor microenvironment to enhance anti-tumor immunity.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:34:27.326Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Other solid tumors (in development)"}]},"trialDetails":[{"nctId":"NCT07450976","phase":"PHASE2","title":"A Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2026-03","conditions":"Biliary Tract Cancer","enrollment":151},{"nctId":"NCT07110571","phase":"PHASE2","title":"A Trial of Adebrelimab Plus (SHR-A1811/SHR-A1904 With Chemotherapy) or SHR-8068 as Treatment for Gastric/GEJ Cancer","status":"RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2025-08-28","conditions":"Gastric Cancer, Gastroesophageal-junction Cancer","enrollment":200},{"nctId":"NCT06547736","phase":"PHASE2","title":"Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-10-14","conditions":"Pancreatic Cancer","enrollment":160},{"nctId":"NCT05277168","phase":"PHASE1, PHASE2","title":"A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2022-05-30","conditions":"Advanced Solid Tumors","enrollment":83},{"nctId":"NCT06350006","phase":"PHASE1","title":"SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid Tumor","status":"RECRUITING","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","startDate":"2024-05-29","conditions":"CLDN18.2-positive Advanced Solid Tumor","enrollment":924},{"nctId":"NCT06520488","phase":"PHASE1, PHASE2","title":"A Study of HRS-4642 in Combination With Antineoplastic Agents in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-08-09","conditions":"Advanced Solid Tumors","enrollment":118},{"nctId":"NCT07102901","phase":"PHASE2","title":"Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-09-05","conditions":"Advanced Gastric Cancer, Metastatic Gastric Cancer, Gastroesophageal Junction Adenocarcinoma","enrollment":351},{"nctId":"NCT04877717","phase":"PHASE1","title":"A Study of SHR-A1904 in Patients With Advanced Solid Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","startDate":"2021-07-01","conditions":"Advanced Solid Cancer","enrollment":107},{"nctId":"NCT06881017","phase":"PHASE2","title":"Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping","status":"NOT_YET_RECRUITING","sponsor":"China Medical University, China","startDate":"2025-05-01","conditions":"Gastric Cancer, HER2 + Gastric Cancer, CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction","enrollment":140},{"nctId":"NCT06649292","phase":"PHASE3","title":"SHR-A1904 Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patitens With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","startDate":"2024-11-22","conditions":"Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","enrollment":524},{"nctId":"NCT04928625","phase":"PHASE1","title":"A Trial of SHR-A1904 in Patients With Advanced Pancreatic Cancer","status":"UNKNOWN","sponsor":"Shanghai Hengrui Pharmaceutical Co., Ltd.","startDate":"2021-08-06","conditions":"Advanced Pancreatic Cancer","enrollment":75}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SHR-A1904","genericName":"SHR-A1904","companyName":"Shanghai Hengrui Pharmaceutical Co., Ltd.","companyId":"shanghai-hengrui-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SHR-A1904 is a bispecific antibody that simultaneously engages PD-1 on immune cells and TGF-β in the tumor microenvironment to enhance anti-tumor immunity. Used for Non-small cell lung cancer, Other solid tumors (in development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}